Form 4: Burning Rock Biotech Director Acquires Shares

Burning Rock Biotech Ltd. Director Yusheng Han has acquired a significant number of ordinary shares represented by American depositary shares (ADS) over several transactions in June 2026.

Summary

• Yusheng Han, a Director at Burning Rock Biotech Ltd., acquired a total of 743,650 ordinary shares, represented by American Depositary Shares (ADS), through multiple transactions between June 11, 2026, and June 26, 2026.
• The acquisitions were made at prices ranging from $7.4503 to $9.2483 per ADS.
• Following these transactions, Han's beneficial ownership of ordinary shares increased, with the total number of shares beneficially owned directly reported as 18,404,086 as of June 26, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing due to the director's consistent acquisition of shares, indicating personal investment and confidence, though it does not provide new financial performance data.

Positives

• Director Yusheng Han demonstrates confidence in the company by acquiring additional shares.
• The acquisition of 743,650 shares indicates a belief in the company's future prospects.

Future Outlook

This filing does not contain forward-looking statements or guidance. It reports on past transactions.

Industry Context

StockSavvy.ai notes that insider share acquisitions by directors can signal confidence in the company's future performance, especially within the competitive biotechnology sector where significant R&D investments and regulatory hurdles are common.

Stakeholder Impact

• Shareholders may view the director's increased shareholding positively, interpreting it as a sign of confidence in the company's future value.
• Employees may be encouraged by the director's commitment, potentially boosting morale.

Key Dates

Recommendation

The filing reports on insider share acquisitions, which is generally a positive signal of management confidence. However, it does not provide new financial performance data or strategic updates that would warrant a strong buy or sell recommendation. Therefore, a 'hold' is appropriate, suggesting investors maintain their current position while awaiting further company developments.

Keywords

Burning Rock Biotech, BNR, Form 4, Insider Trading, Share Acquisition, Director, American Depositary Shares, SEC Filing